Saturday, October 3, 2026

Nikkei 225 Is 5% Up In The Last 10 Sessions

ViaNews Editorial Team

February 1, 2023

Nikkei 225 Is 5% Up In The Last 10 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 5.22% for the last 10 sessions. At 20:08 EST on Tuesday, 31 January, Nikkei 225 (N225) is $27,504.43.

About Nikkei 225's yearly highs and lows, it's 11.44% up from its 52-week low and 5.88% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was 0.86%, 0.05%, and 0.80%, respectively.

Nikkei 225's highest amplitude of average volatility was 1.63% (last week), 0.87% (last month), and 0.80% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to MarketWatch on Monday, 30 January, "The stock has plummeted 87.2% over the past 12 months through Friday, while the S&P 500 has lost 8.2%."
  • According to MarketWatch on Monday, 30 January, "The company's stock has gained 18.7% over the past year, while the S&P 500 is down 4.3%."
  • According to Business Insider on Monday, 30 January, "As of 7.10 am ET, the Dow futures were sliding 221.00 points, the S&P 500 futures were down 36.50 points and the Nasdaq 100 futures were declining 147.00 points.", "The Nasdaq jumped 109.30 points or 1.0 percent to 11,621.71, the S&P 500 rose 10.13 points or 0.3 percent to 4,070.56 and the Dow inched up 28.67 points or 0.1 percent to 33,978.08."
  • According to FXStreet on Monday, 30 January, "Against this backdrop, the US 10-year Treasury yields remain lackluster near 3.51% after snapping a two-week downtrend whereas the S&P 500 Futures print mild losses."

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com